Safety and tolerability of docetaxel with cyclophosphamide for early breast cancer

Japanese Journal of Cancer and Chemotherapy

Volumn 37, Issue 5, 2010, Pages 835-839

  Kawabata, Hidetaka ^a   Iwatani, Tsuguo ^a   Makuuchi, Rie ^a   Miura, Daishu ^a   Suzuki, Noriyuki ^a   Nakazawa, Hideki ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Breast neoplasms; Docetaxel; Toxicity

Indexed keywords

ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN;

ARTICLE; ASTHENIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ASSESSMENT; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FEBRILE NEUTROPENIA; HEMATOLOGIC DISEASE; HUMAN; MAJOR CLINICAL STUDY; MYALGIA; NEUROPATHY; OUTCOME ASSESSMENT; SKIN TOXICITY; TREATMENT RESPONSE;

EID: 79960821061     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Hayes DF, Thor AD and Dressler LG: HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357: 1496-1506, 2007. (Pubitemid 47572635)
2. Jones S, Holmes FA, O'shaughnessy J, et al: Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 27: 1177-1183, 2009.
3. Jones SE, Savin MA, Holmes FA, et al: Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24: 5381-5387, 2006. (Pubitemid 46623169)
4. Takabatake D, Taira N, Hara F, et al: Feasibility study of docetaxel with cyclophosphamide as adjuvant chemotherapy for Japanese breast cancer patients. Jpn J Clin Oncol 39: 478-483, 2009.
5. Schwartz J, Domchek SM, Hwang WT, et al: Evaluation of anemia, neutropenia and skin toxicities in standard or dose-dense doxorubicin/ cyclophosphamide (AC)-paclitaxel or docetaxel adjuvant chemotherapy in breast cancer. Ann Oncol 16: 247-252, 2005. (Pubitemid 40309304)
6. Lambert-Falls R and Modugno S: Toxicity of dose-dense docetaxel followed by doxorubicin with cyclophosphamide as adjuvant therapy for breast cancer in a phase II study. Clin Breast Cancer 7: 697-704, 2007. (Pubitemid 47344732)
7. Gianni L: Anthracyclines and Early Breast Cancer: The End of an Era ? J Clin Oncol 27: 1155-1157, 2009.
8. Swain SM, Jeong JH, Geyer CE, et al: NSABP B-30: Definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer. abstract 75, SABCS 2008.
9. Eiermann W, Pienkowski T, Crown J, et al: BCIRG 005 main efficacy analysis: a phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC→T) in women with Her-2/neu negative axillary lymph node positive early breast cancer. abstract 77, SABCS 2008.